# Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC

> **NCT06552234** · PHASE2 · RECRUITING · sponsor: **Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer** · enrollment: 30 (estimated)

## Conditions studied

- NSCLC Stage IV
- NSCLC, Stage III

## Interventions

- **DRUG:** Repotrectinib

## Key facts

- **NCT ID:** NCT06552234
- **Lead sponsor:** Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-01
- **Primary completion:** 2031-09
- **Final completion:** 2031-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06552234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06552234, "Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06552234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*